NRAS and acute myeloid leukemia: By demonstrating that miR-708 can effectively suppress NRAS-mutated cancer, including melanoma, AML, and NSCLC progression, we offer an opportunity to use miR-708 as precision medicine for NRAS mutation-driven cancer, and further explore a new era of miRNA-based drug development in precision cancer therapy.